Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile2 entries
2023
Audit Office Says Livzon Pharmaceutical Extracted Funds Through Employee Consulting Firm for Drug PR
A National Audit Office investigation disclosed that Livzon Pharmaceutical extracted RMB 12.4001 million through consulting companies set up by employees for drug “public relations.” The company said it was verifying the matter. It drew attention amid the pharmaceutical anti-corruption backdrop.
2011
Subsidiary Banned from Shanghai Drug and Device Market for Two Years Over Bribery
Livzon Group subsidiary Zhuhai Livzon Diagnostics was listed for bad records in Shanghai due to commercial bribery and barred for two years from Shanghai pharmaceutical and medical device procurement and tendering; the company said it was the personal behavior of a salesperson, but was questioned over untimely disclosure. Brand compliance was called into question.